These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A computational study on active constituents of Shamsi S; Anjum H; Shahbaaz M; Khan MS; Ataya FS; Alamri A; Alhumaydhi FA; Husain FM; Rehman MT; Mohammad T; Islam A; Anjum F; Shamsi A J Biomol Struct Dyn; 2022 Oct; 40(17):7702-7713. PubMed ID: 33759703 [TBL] [Abstract][Full Text] [Related]
4. Targeting SARS-CoV-2 main protease: structure based virtual screening, in silico ADMET studies and molecular dynamics simulation for identification of potential inhibitors. Uniyal A; Mahapatra MK; Tiwari V; Sandhir R; Kumar R J Biomol Struct Dyn; 2022 May; 40(8):3609-3625. PubMed ID: 33226303 [TBL] [Abstract][Full Text] [Related]
5. Identification of potent COVID-19 main protease inhibitors by loading of favipiravir on Mg Al-Shuaeeb RAA; Abd El-Mageed HR; Ahmed SA; Mohamed HS; Hamza ZS; Rafi MO; Rahman MS J Biomol Struct Dyn; 2023; 41(21):11437-11449. PubMed ID: 36591698 [TBL] [Abstract][Full Text] [Related]
6. Natural phyto, compounds as possible noncovalent inhibitors against SARS-CoV2 protease: computational approach. Ogidigo JO; Iwuchukwu EA; Ibeji CU; Okpalefe O; Soliman MES J Biomol Struct Dyn; 2022 Mar; 40(5):2284-2301. PubMed ID: 33103616 [TBL] [Abstract][Full Text] [Related]
8. A higher flexibility at the SARS-CoV-2 main protease active site compared to SARS-CoV and its potentialities for new inhibitor virtual screening targeting multi-conformers. Rocha REO; Chaves EJF; Fischer PHC; Costa LSC; Grillo IB; da Cruz LEG; Guedes FC; da Silveira CH; Scotti MT; Camargo AD; Machado KS; Werhli AV; Ferreira RS; Rocha GB; de Lima LHF J Biomol Struct Dyn; 2022; 40(19):9214-9234. PubMed ID: 33970798 [TBL] [Abstract][Full Text] [Related]
9. Exploring potential inhibitor of SARS-CoV2 replicase from FDA approved drugs using insilico drug discovery methods. Chandra A; Gurjar V; Ahmed MZ; Alqahtani AS; Qamar I; Singh N J Biomol Struct Dyn; 2022 Aug; 40(12):5507-5514. PubMed ID: 33491573 [TBL] [Abstract][Full Text] [Related]
10. Isatin-based virtual high throughput screening, molecular docking, DFT, QM/MM, MD and MM-PBSA study of novel inhibitors of SARS-CoV-2 main protease. Varadharajan V; Arumugam GS; Shanmugam S J Biomol Struct Dyn; 2022 Oct; 40(17):7852-7867. PubMed ID: 33764269 [TBL] [Abstract][Full Text] [Related]
11. Computational basis of SARS-CoV 2 main protease inhibition: an insight from molecular dynamics simulation based findings. Avti P; Chauhan A; Shekhar N; Prajapat M; Sarma P; Kaur H; Bhattacharyya A; Kumar S; Prakash A; Sharma S; Medhi B J Biomol Struct Dyn; 2022; 40(19):8894-8904. PubMed ID: 33998950 [TBL] [Abstract][Full Text] [Related]
12. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the effects of chlorhexidine and several flavonoids as antiviral purposes on SARS-CoV-2 main protease: molecular docking, molecular dynamics simulation studies. Tatar G; Salmanli M; Dogru Y; Tuzuner T J Biomol Struct Dyn; 2022 Oct; 40(17):7656-7665. PubMed ID: 33749547 [TBL] [Abstract][Full Text] [Related]
20. Identification of a potential SARS-CoV2 inhibitor via molecular dynamics simulations and amino acid decomposition analysis. Razzaghi-Asl N; Ebadi A; Shahabipour S; Gholamin D J Biomol Struct Dyn; 2021 Oct; 39(17):6633-6648. PubMed ID: 32705953 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]